CEVEC Pharmaceuticals GmbH

General information
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen-Str. 60 – 62
51105 Köln, North Rhine-Westphalia
Germany

Contact person: Nicole Faust, CEO
Company main phone: +49 (221) 46020800
Company main fax:  +49 (221) 46020801
Website:  www.cevec.com
Year founded:2003
Source of foundation:Spin-off from university
Name of foundation source:University of Cologne, Germany
Corporate description / mission:
CEVEC Pharmaceuticals is a provider of high-performance cell technology for the manufacturing of advanced biotherapeutics from R&D to manufacturing scale. The company’s product portfolio comprises platform technologies for gene therapy viral vectors, viral vaccines, Exosomes and complex recombinant proteins. ELEVECTA® is specifically designed for AAV manufacturing, while CAP® addresses Adenoviral vectors, Lentiviral vectors, Oncolytic viruses and Exosomes. CAP®Go is the platform of choice for complex recombinant proteins.
State of ownership: Private / independent
Headquarters: Yes
Categorization
Sector:
  • Biotechnology - R&D Services
Subsector:
  • Cell culture
  • CMO (Contract Manufacturing Organization)
  • Fill & finish
  • Synthesis services
Primary therapeutic areas:
  • Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
Business model:
  • Manufacturer
  • Out-licensing
  • Research on contract basis
  • Supplier / Distributor
Customer segments:
  • Other
  • Large biotech & big pharma
  • Small biotech
Summary Products / Services / Technologies
Description of products:
RCA-FREE ADENOVIRAL VECTORS
STABLE AAV PRODUCER CELL LINES
VIRAL VECTORS, VACCINES AND EXOSOMES
GLYCO-OPTIMIZED PROTEINS
Technology used:
ELEVECTA®
CAP®
CAP® Ad
CAP® Go
Financing details
Financing details:
On April 2019, the company closed Series D financing round with new and existing investors. The funding will be allocated to the expansion and commercialization of CEVEC’s CAP®GT-based stable adeno-associated viral (AAV) vector production platform and to the broadening of the Company’s technology portfolio.
Collaborations & Clients
Partnering strategy / collaborations:
09 Feb 2017: CEVEC announces exclusive license agreement with NewLink Genetics for the use of its proprietary CAP(R)GT and CAP(R)GO cell lines in the development and commercialization of products for the treatment and prophylaxis of Zika virus infections.
X